Healthcare Systems & Policy

Securing both FDA and EU MDR Class 2A certification unlocks acceptance in most global markets, with US entry as the key value inflection for the next funding round and China's 100M COPD patients representing a massive underserved opportunity.

CEO highlights that securing both EU Class 2A and FDA clearance creates a regulatory passport accepted by most global markets, making US entry the critical milestone for worldwide scale — a common but underappreciated pathway for medtech companies.

By eliminating insurance middlemen, HIMS offers upfront pricing ($50 vs $175 via insurance) and removes prior-authorization delays. Competitor Ro charges monthly fees for insurance handling; HIMS's pure DTC model creates structural cost and experience advantages.

The FDA's review of peptide compounding eligibility represents a structural policy shift that could legitimize direct-to-consumer peptide therapies outside traditional insurance reimbursement, benefiting platforms that control the end-to-end experience from diagnostics to fulfillment.

Steamfield recruited an FDA reviewer (expert in needles/lasers) to navigate the 510(k) clearance pathway, demonstrating a playbook for medtech startups to de-risk regulatory timelines by embedding regulatory expertise.

Classifying hair regrowth as a medical device rather than drug cuts regulatory timeline from 10+ years to months, enabling faster commercialization and attracting established aesthetic distributors (e.g., Turkey's top Dysport seller) to fund clinical trials.

The ACA individual market has shown 3.2% average annual cost trends versus 20-30% in fully insured small group markets, proving the model can deliver healthcare cost growth below inflation.

By allowing individuals to choose and keep their provider networks across life stages, insurers gain longer investment horizons, higher lifetime member value, and incentives for preventive care that lower overall costs.

US healthcare's employer-insurer-provider incentives allow persistent price increases post-launch, while European single-payer systems systematically push drug/device prices down, making US the primary commercialization market for health tech innovation.

Unlimited federal funding (student loans, Medicare/Medicaid, housing subsidies) removes price discipline, causing 6x admin growth in education and unaffordable healthcare/housing; ending federal student loan program would solve 90% of education cost crisis.

Traditional healthcare incentives push prices up (pharma, insurance, doctors all benefit from higher costs). HIMS's platform model flips this: scale allows lower prices to serve 10-25M patients vs. doctor's limited daily capacity, making the supplier a commodity and the platform the primary relationship.

By refusing insurance contracts, Hims & Hers maintains pricing transparency and control, disintermediating pharmacies (CVS, Walgreens) and traditional prescribers; this structural cost advantage lets them undercut incumbents while capturing full margin, a model that could reshape healthcare delivery globally.

By eliminating insurance intermediaries, Hims & Hers delivers upfront price transparency and lower all-in costs (e.g., $82/month inclusive vs. $175 insurance-billed), attracting consumers to treat more conditions. This structural cost advantage pressures incumbents and expands the addressable market beyond insurance-constrained populations.

HIMS is executing an aggregator strategy: acquire demand (subscribers) across geographies, then leverage that user base to attract supply partners (GLP-1 manufacturers, lab services, peptide providers) onto the platform. Vertical integration (compounding) is a means to enable personalized low-cost prescriptions, not an end state. The platform power position emerges at 3-4M+ subscribers.

Platforms like HIMS that operate on cash-pay models can directly compare branded vs compounded GLP-1s on price and efficacy, unlike insurance-mediated traditional care, enabling them to become the primary portal for metabolic drug access.

By adding labs, AI, and membership layers, the company moves from high customer acquisition cost for one-time prescriptions to a recurring revenue platform that tracks health over time, integrates wearable data, and expands into new categories like peptides and cancer screening.

By moving profitability to a $150/month membership fee rather than prescription markups, Hims & Hers aligns its incentives with consumers — the platform profits by lowering drug costs and adding value, similar to Costco's model, potentially disrupting traditional pharmacy economics.

FDA can restrict what can be compounded, threatening HIMS's core personalized treatment model; shift to branded GLP-1s would compress margins and require pharma partnerships HIMS has struggled to secure.

Individual Coverage Health Reimbursement Arrangements (ICHRA) move employers from defined-benefit to defined-contribution health benefits, mirroring the 401(k) transition; Oscar built the 'rails' for ICHRA with competitors (Aflac, VSP, Mark Cuban Cost Plus, Eli Lilly, imaging startups) to capture 115M small group lives, 30M gig workers, and 5-10M Medicaid transitions, creating a 200M member opportunity where Oscar's tech platform and narrow networks win on consumer experience.

Risk adjustment equalizes insurer risk pools, removing incentive to cherry-pick healthy members; Oscar's narrow networks and condition-specific products (diabetes, menopause, COPD) attract high-risk members profitably, delivering healthcare cost growth below inflation (3.2% vs 20-30% in fully insured small group) — a structural proof point for consumer-directed individual markets.

Four major payers + consolidated hospital systems = negotiated loggerheads inflating costs (2x for same primary care). AI-native insurers can undercut on admin (9%→near-zero) and align incentives toward prevention without legacy workforce constraints.

Galleri's CLIA-regulated, prescription-only, non-insurance-covered test generates growing revenue purely from consumer self-pay — mirroring Hims' direct-to-consumer model; demonstrates patients value early detection enough to pay out-of-pocket, creating a parallel value chain that incumbents and analysts underestimate because they view healthcare through insurance-reimbursement lens.

As diagnostic cost and convenience exponentially improve (single source of truth via exhaustive biomarkers), power shifts from providers to patients who own their data and use AI to interpret it, fundamentally restructuring healthcare market dynamics.

The traditional top-down, regulation-protected healthcare model is dissolving because biomarkers and AI give patients direct insight into molecular-level health drivers; litigation by incumbents signals lost marketplace edge per Eric Schmidt's model.

The industry is shifting from 'pay when you're about to die' to 'pay to stay healthy' with data transparency, driven by personalized peptides and longitudinal data networks that compound value over decades as material abundance spreads.

Tempus operates within the insurance reimbursement system where AI-generated clinical insights are not yet reimbursed at scale, creating a structural headwind versus cash-pay models like Hims; the thesis depends on reimbursement codes catching up to AI diagnostic value.

Hims operates a 'Costco algorithm' — continuously sharing scale economies with customers via lower prices and expanded biomarker solutions. This builds top-of-funnel dominance and creates dual-sided network effects: more patients improve data quality for drug providers, while more drug providers improve personalized offerings for patients, locking in long-term platform power.

Structural shift from Pharma 1.0 (disease drugs, payer-funded, health system distribution) to Pharma 2.0 (wellness drugs, consumer-funded, DTC distribution). Eli Lilly/Novo poorly positioned for consumer marketing and longitudinal experience. Vertically integrated platforms (Hims, Superpower) that own patient relationship and supply chain will capture Pharma 2.0 value. Costco-algorithm on biomarkers (exhaustive, frequent, low-cost) creates defensible moat.

The fundamental incentive divergence — D2C platforms earn when customers stay healthy (subscription/LaaS) while hospitals earn when patients get sick (fee-for-service) — creates a structural tailwind for direct-to-consumer preventive care platforms to capture the growing longevity spend, with AI compressing hospital intelligence into algorithms that can be delivered via preferred D2C channels.

Medicaid reductions from federal budget legislation will shutter rural hospitals operating at deficits, shifting costs to private insurance and creating a negative feedback loop for rural healthcare access.

760K physicians operate on cash basis, ~13K hospitals/facilities on revenue basis, and ~1,300 insurers plus pharma/device on margin basis. This structural misalignment means no single actor optimizes for total system value. Shift to individual purchasing (consumer cash basis) would force alignment, but incumbents use regulatory capture to block change — a classic Machiavellian 'new order' problem.

Employer-sponsored insurance creates misaligned incentives: large networks are inversely cost-effective, small groups face double-digit rate increases from single events, and employees get one-size-fits-all benefits. ICHRA (Individual Coverage HRA) lets employers define-contribute while employees choose narrow-network ACA plans tailored to their needs — 75% of providers already in ACA networks. This mirrors the DB-to-DC pension shift.

Almost all healthcare dysfunction stems from the consumer not being the customer. Employers create churn and misaligned incentives; shifting to consumer-directed purchasing (like AT&T phone plans) would create longitudinal relationships and force providers/PBMs to compete on consumer value.

Society should worry far more about the next Hepatitis C cure (which dropped from $100k to $15k in 6 months) not being invented than about Humira's patent thicket. The learning curve for biologics is the steepest of any technology; optimizing for marginal patent reform distracts from funding breakthrough innovation.

Rebates (40-50% of list price) destroy price signals for consumers and providers. Removing them would restore genuine price competition between drugs. PBMs currently optimize for payer (employer/government) cost, not consumer outcomes; true reform requires making the consumer the arbiter of drug choice.

Third-party payer and asymmetric information create inherent market failures requiring massive regulation; private actors continuously arbitrage rules (cat-and-mouse), necessitating active regulatory maintenance rather than deregulation.

Medicines exist for all five core drivers of mortality (statins/PCSK9 for lipids, GLP-1s for cardiometabolic, anti-amyloid for neuro, anti-inflammatories, antihypertensives) but systemic friction (complexity, cost, compliance) prevents utilization. GLP-1 commercialization proves the model: remove friction, lower cost, simplify dosing → mass adoption. Trillion-dollar annual healthcare savings achievable.